Prescribing cyclic antidepressants for vitiligo patients: which agents are superior, which are not?
Namazi
Mohammad Reza
MR
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D003891:Desipramine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009638:Norepinephrine / Q000097:blood*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D016896:Treatment Outcome; D014299:Trimipramine / Q000009:adverse effects / Q000627:therapeutic use; D014820:Vitiligo / Q000523:psychology*
D018759:Adrenergic Uptake Inhibitors; D000929:Antidepressive Agents, Tricyclic; D018680:Cholinergic Antagonists; D011976:Receptors, Muscarinic; D000639:Amitriptyline; D014299:Trimipramine; D003891:Desipramine; D009638:Norepinephrine